Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024 18:45 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
August 22, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
August 09, 2024 17:59 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways...
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
July 24, 2024 06:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
July 11, 2024 07:15 ET
|
Skye Bioscience, Inc.
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
July 11, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
July 03, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
July 01, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
June 25, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
June 10, 2024 07:00 ET
|
Skye Bioscience, Inc.
SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued Phase 2 study of Nimacimab in obesity expected to start in Q3 2024 Cash runway extended into...